Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | JAK1 | P23458 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.34 |
| ▸ | MPO | P05164 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.33 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1703270 | 1.00 | LRRK2 (0.40) | LRRK2JAK2NAMPTMKNK1MKNK2 | |
| SCHEMBL12598741 | 1.00 | LRRK2 (0.40) | LRRK2JAK2NAMPTMKNK1MKNK2 | |
| SCHEMBL15652587 | 0.90 | BMPR1A (0.37) | LRRK2JAK2NAMPTMKNK1MKNK2 | |
| SCHEMBL1422774 | 0.89 | MET (0.41) | LRRK2JAK2MKNK1KDM5AJAK1 | |
| Hydrochloric Acid SCHEMBL16593449 | 0.88 | MET (0.42) | LRRK2JAK2MKNK1KDM5AJAK1 | |
| Hydrochloric Acid SCHEMBL15875304 | 0.88 | MET (0.42) | LRRK2JAK2MKNK1KDM5AJAK1 | |
| SCHEMBL2574462 | 0.85 | KIT (0.48) | LRRK2JAK2MKNK1MKNK2KIT | |
| SCHEMBL28484611 | 0.85 | KDM5A (0.34) | LRRK2JAK2KITKDM5AMET | |
| SCHEMBL10191777 | 0.81 | IRAK4 (0.38) | LRRK2JAK2MKNK1KDM5AJAK1 | |
| SCHEMBL25249934 | 0.79 | LRRK2 (0.40) | LRRK2JAK2NAMPTMKNK1MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304567-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-10-02 | — | — | US | disclosed |
| CN-115023428-B | Pyrimidopyrroles compounds | 江苏先声药业有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-115244055-B | Pyrimidine five-membered ring derivative and application thereof | 江苏先声药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-115244055-A | Pyrimido five-membered ring derivative and application thereof | 江苏先声药业有限公司 | 2022-10-25 | — | — | CN | disclosed |
| CN-115023428-A | Pyrimidopyrroles | 江苏先声药业有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-02-25 | — | — | US | disclosed |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-02-25 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| WO-2015123722-A1 | INHIBITORS | BIONOMICS LIMITED (AU) | 2015-08-27 | — | — | WO | disclosed |
| WO-2014139145-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014139465-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
| US-8426408-B2 | Pyrimidine inhibitors of kinases | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2440548-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | Abbott Laboratories (US) | 2012-04-18 | — | — | EP | disclosed |
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | US | disclosed |
| WO-2010144468-A1 | 2- ( LH-PYRAZOL-4 -YLAMINO ) -PYRIMIDINE AS KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317680-A1 | PYRIMIDINE INHIBITORS OF KINASES | AURKA, AURKC, AURKB | LRRK2 1841/4885JAK2 256/4885NAMPT 909/4885 |
| US-20250304567-A1 | PYRROLIDIONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | LRRK2 551/4885JAK2 517/4885NAMPT 1753/4885 |
| US-20160052926-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF | FGFR3, FGFR1, FGFR4 | LRRK2 236/4885JAK2 11/4885NAMPT 574/4885 |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | FGFR3, FGFR1, FGFR4 | LRRK2 219/4885JAK2 12/4885NAMPT 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.